Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6535
    +0.0012 (+0.18%)
     
  • OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD

    2,349.60
    +7.10 (+0.30%)
     
  • Bitcoin AUD

    96,436.22
    -2,088.80 (-2.12%)
     
  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     
  • AUD/EUR

    0.6108
    +0.0035 (+0.57%)
     
  • AUD/NZD

    1.0994
    +0.0037 (+0.33%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,718.30
    +287.79 (+1.65%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,239.66
    +153.86 (+0.40%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Company News for Nov 7, 2019

  • Shares of Venator Materials PLC VNTR increased 24.6% after the chemical products manufacturer reported Q3 earnings of $0.08 per share, surpassing the Zacks Consensus Estimate of $0.03.

  • Shares of Aquestive Therapeutics, Inc. AQST gained 23.6% after the specialty pharmaceutical company reported Q3 revenues of $12.42 million which beat the Zacks Consensus Estimate by 20.39%.

  • Shares of Plantronics, Inc. PLT declined 36.6% after the company reported Q3 earnings per share of $1.24, which missed the Zacks Consensus Estimate of $1.32.

  • Shares of WW International, Inc. WW lost 14.8% after the weight management services provider reported Q3 revenues of $348.57 million, which missed the Zacks Consensus Estimate by 2.26%.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Plantronics, Inc. (PLT) : Free Stock Analysis Report
 
Venator Materials PLC (VNTR) : Free Stock Analysis Report
 
WW International, Inc. (WW) : Free Stock Analysis Report
 
Aquestive Therapeutics, Inc. (AQST) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research